Ergocalciferol is an inactivated vitamin D analog. It is synthesized by some plants in the presence of UVB light. The production of ergocalciferol was prompted by the identification of dietary deficiency, more specifically vitamin D, as the main causative factor for the development of rickets. Ergocalciferol was isolated for the first time from yeast in 1931...
Ergocalciferol is indicated for the treatment of hypoparathyroidism, refractory rickets, and familial hypophosphatemia.
Hypoparathyroidism is the result of inadequate parathyroid hormone production that occurs due to the presence of damage or removal of the parathyroid glands. This condition produces decreased calcium and increased phosphorus levels.
...
King Faisal Specialist Hospital & Research Center, Riyadh, Central, Saudi Arabia
bellevue hospital CTSI, New York, New York, United States
University of Utah, Salt Lake City, Utah, United States
Sino-Japanese Friendship Hospital, Beijing, Beijing, China
People's Liberation Army Air Force General Hospital, Beijing, Beijing, China
People's Liberation Army General Hospital, Beijing, Beijing, China
Childrens Hospital Los Angeles, Los Angeles, California, United States
Loma Linda University, Loma Linda, California, United States
The People's Hospital of Peking University, Beijing, Beijing, China
Beijing Friedship Hospital, Beijing, Beijing, China
Men's Health Boston, Chestnut Hill, Massachusetts, United States
Montefiore Medical Center / Weiler division, Bronx, New York, United States
Jacobi Medical Center, Bronx, New York, United States
Cedars-Sinai Medical Center, Los Angeles, California, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.